CEPTOR RETAINS BANYAN BIOMARKERS TO DEVELOP TEST TO EVALUATE EFFECTIVENESS OF MYODUR FOR MUSCULAR DYSTROPHY

CepTor Corporation, a development-staged biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that Banyan Biomarkers, Inc. has been retained to identify a biomarker assay that evaluates the usefulness of Myodur for treating Duchenne Muscular Dystrophy (DMD) in children. Biomarkers, proteins found in body fluids, are crucial in determining a drug's efficacy and toxicity and have the potential to significantly reduce a company's clinical trial costs and duration.
Genetic Engineering News